Dinutuximab beta plus chemo for childhood neuroblastoma after relapse
Part of Cancer, Immune system & allergy clinical trials.
This Phase 1 trial tests a combination of dinutuximab beta (an immunotherapy) and chemotherapy in children with high-risk neuroblastoma that did not respond to standard treatment or has come back or progressed. It aims to see how well the treatment works and how safely it can be given in this situation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must have neuroblastoma that fits international diagnostic criteria (INRG).
- Age must be 1 to 18 years, with high-risk neuroblastoma that is refractory, relapsed, or has progressed.
- Organ function must be adequate, or any problems must be below a certain severity level (grade 4 or less).
- Your child must have a life expectancy of at least 6 months.
- A parent/guardian must be able to give written consent for the study treatment.
- If the participant could become pregnant: they must agree to effective birth control; breastfeeding must stop.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding the antibody dinutuximab-beta to standard chemotherapy for children and young adults with newly diagnosed high-risk neuroblastoma. The goal is to see if this combination helps the immune system fight the cancer better.
This study tests whether giving fewer chemotherapy drugs along with other targeted therapies (monoclonal antibodies) works well for children with high-risk neuroblastoma. It aims to reduce side effects while still treating the cancer effectively.
This study tests adding two medications (naxitamab and GM-CSF) to standard chemotherapy for children and young adults with newly diagnosed high-risk neuroblastoma, a cancer of nerve cells. The goal is to help the body's immune system fight the cancer more effectively.
This Phase 3 study tests treatment strategies for children with high-risk neuroblastoma, aiming to improve how well the cancer responds and how long patients can stay in control. It compares different intensities and add-ons at key treatment steps depending on your child’s response and health.
This trial tests adding a targeted drug called dinutuximab to standard chemotherapy, surgery, and a stem cell transplant for children and young adults with a new diagnosis of high-risk neuroblastoma. The goal is to see if this combination helps more patients stay in remission.
This trial combines the immunotherapy drug dinutuximab beta with two different chemotherapy regimens to see if it works better for children with high-risk neuroblastoma that has spread. It may be an option for newly diagnosed patients who have not had cancer treatment before.
Hear when a new High-Risk Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.